Gegenanzeigen · Camzyos
CAMZYOS 2.5 mg hard capsules CAMZYOS 5 mg hard capsules CAMZYOS 10 mg hard capsules CAMZYOS 15 mg hard capsules · Abschnitt 4.3 · PDF-Seite 8
HOS-147592 · Präparat HOS-099694
▪ Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. ▪ During pregnancy and in women of childbearing potential not using effective contraception (see sections 4.4 and 4.6). ▪ Concomitant treatment with strong CYP3A4 inhibitors in patients with CYP2C19 poor metaboliser phenotype and undetermined CYP2C19 phenotype (see sections 4.2, 4.4 and 4.5). ▪ Concomitant treatment with the combination of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-02T15:36:00Z · SHA-256 9132b2e8e8aaa16319c50ba4cee221a3197217762e259ff316f0a88969d8e68f · Passage 0778aa633182388319cb3a6eabc02fa8016bc6caeb6e695c16b6fdc74aa1ce89 · Zeichen 0–545 im Abschnitt